Compare
Twist Bioscience Corp vs ADMA Biologics, Inc. vs Repligen Corp vs Adaptive Biotechnologies Corp
| Latest fiscal year | Twist Bioscience Corp TWST | ADMA Biologics, Inc. ADMA | Repligen Corp RGEN | Adaptive Biotechnologies Corp ADPT |
|---|---|---|---|---|
| Year ended | 2026-09-30 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $459.43M | $510.17M | $738.26M | $276.98M |
| Revenue growth (YoY) | +22.0% | +19.6% | +16.4% | +54.8% |
| Gross margin | 52.4% (computed) | 57.4% | 52.3% (computed) | 74.2% (computed) |
| Operating margin | -30.4% | 37.5% | 7.5% | -20.6% |
| Net margin | -28.3% | 28.8% | 6.6% | -21.5% |
| Net income | -$130.20M | $146.93M | $48.89M | -$59.50M |
| EPS (Diluted) | -$2.08 | $0.60 | $0.86 | -$0.39 |
| Operating cash flow | -$41.43M | $50.40M | $117.42M | -$45.99M |
| Free cash flow | -$89.01M | $27.82M | $93.90M | -$48.95M |
| Cash & equivalents | $533.99M | $87.63M | $566.02M | $70.50M |
| Total assets | $1.12B | $624.24M | $2.95B | $512.74M |
| Total liabilities | $233.79M | $146.92M | $843.57M | $287.74M |
| Shareholders' equity | $888.02M | $477.32M | $2.11B | $218.79M |
| Return on year-end equity | -14.7% | 30.8% | 2.3% | -27.2% |
| Shares outstanding | 67.81M | 237.87M | 56.33M | 153.78M |
Revenue, most recent five fiscal years
| Fiscal year | Twist Bioscience Corp | ADMA Biologics, Inc. | Repligen Corp | Adaptive Biotechnologies Corp |
|---|---|---|---|---|
| Latest | $459.43M Ended 2026-09-30 | $510.17M Ended 2025-12-31 | $738.26M Ended 2025-12-31 | $276.98M Ended 2025-12-31 |
| 1 year earlier | $376.57M Ended 2025-09-30 | $426.45M Ended 2024-12-31 | $634.44M Ended 2024-12-31 | $178.96M Ended 2024-12-31 |
| 2 years earlier | $312.97M Ended 2024-09-30 | $258.21M Ended 2023-12-31 | $632.36M Ended 2023-12-31 | $170.28M Ended 2023-12-31 |
| 3 years earlier | $245.11M Ended 2023-09-30 | $154.08M Ended 2022-12-31 | $801.54M Ended 2022-12-31 | $185.31M Ended 2022-12-31 |
| 4 years earlier | $203.56M Ended 2022-09-30 | $80.94M Ended 2021-12-31 | $670.53M Ended 2021-12-31 | $154.34M Ended 2021-12-31 |